<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Almanac of Clinical Medicine</journal-id><journal-title-group><journal-title xml:lang="en">Almanac of Clinical Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Альманах клинической медицины</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2072-0505</issn><issn publication-format="electronic">2587-9294</issn><publisher><publisher-name xml:lang="en">Moscow Regional Research and Clinical Institute (MONIKI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">7751</article-id><article-id pub-id-type="doi">10.18786/2072-0505-2023-51-012</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Intraoperative computed tomography perfusion navigation for maximal resection of high grade gliomas: a prospective non-randomized trial</article-title><trans-title-group xml:lang="ru"><trans-title>Использование интраоперационной компьютерной томографической навигации с перфузионным исследованием в достижении максимальной резекции злокачественных глиом: проспективное нерандомизированное исследование</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3820-2057</contrib-id><name-alternatives><name xml:lang="en"><surname>Talybov</surname><given-names>Rustam S.</given-names></name><name xml:lang="ru"><surname>Талыбов</surname><given-names>Рустам Сабирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Radiologist, Head of Department of X-ray Diagnostics</p></bio><bio xml:lang="ru"><p>врач-рентгенолог, заведующий отделением лучевой диагностики</p></bio><email>rustam230789@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4871-2341</contrib-id><name-alternatives><name xml:lang="en"><surname>Trofimova</surname><given-names>Tatyana N.</given-names></name><name xml:lang="ru"><surname>Трофимова</surname><given-names>Татьяна Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, Corr. Member of Russ. Acad. Sci., Chief Research Fellow, Laboratory of Neurovisualization</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор, чл.-корр. РАН, гл. науч. сотр. лаборатории нейровизуализации</p></bio><email>ttrofimova@groupmmc.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0608-8915</contrib-id><name-alternatives><name xml:lang="en"><surname>Mochalov</surname><given-names>Vadim V.</given-names></name><name xml:lang="ru"><surname>Мочалов</surname><given-names>Вадим Васильевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Radiologist</p></bio><bio xml:lang="ru"><p>врач-рентгенолог</p></bio><email>luther1992@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9761-1198</contrib-id><name-alternatives><name xml:lang="en"><surname>Shvetsov</surname><given-names>Ivan V.</given-names></name><name xml:lang="ru"><surname>Швецов</surname><given-names>Иван Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Acting Chief Physician</p></bio><bio xml:lang="ru"><p>канд. мед. наук, и.о. главного врача</p></bio><email>shved1906@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1180-4886</contrib-id><name-alternatives><name xml:lang="en"><surname>Spasennikov</surname><given-names>Vladislav V.</given-names></name><name xml:lang="ru"><surname>Спасенников</surname><given-names>Владислав Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>6th Year Student, Faculty of General Medicine</p></bio><bio xml:lang="ru"><p>студент 6-го курса лечебного факультета</p></bio><email>acrispire@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Regional Clinical Hospital No. 2 (Tyumen)</institution></aff><aff><institution xml:lang="ru">ГБУЗ ТО «Областная клиническая больница № 2»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">N.P. Bechtereva Institute of the Human Brain</institution></aff><aff><institution xml:lang="ru">ФГБУН «Институт мозга человека им. Н.П. Бехтеревой» РАН</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Tyumen State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Тюменский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-06-16" publication-format="electronic"><day>16</day><month>06</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-08-02" publication-format="electronic"><day>02</day><month>08</month><year>2023</year></pub-date><volume>51</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><history><date date-type="received" iso-8601-date="2023-04-14"><day>14</day><month>04</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-06-05"><day>05</day><month>06</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Talybov R.S., Trofimova T.N., Mochalov V.V., Shvetsov I.V., Spasennikov V.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Талыбов Р.С., Трофимова Т.Н., Мочалов В.В., Швецов И.В., Спасенников В.В.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Talybov R.S., Trofimova T.N., Mochalov V.V., Shvetsov I.V., Spasennikov V.V.</copyright-holder><copyright-holder xml:lang="ru">Талыбов Р.С., Трофимова Т.Н., Мочалов В.В., Швецов И.В., Спасенников В.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://almclinmed.ru/jour/article/view/7751">https://almclinmed.ru/jour/article/view/7751</self-uri><abstract xml:lang="en"><p><bold>Background</bold>: The main purpose of surgery for glioblastoma is to ensure the maximally possible cytoreduction. Computed tomography perfusion imaging has non-invasive tools for assessment of tumor blood flow and allows for visualization of the tumor borders and its most malignant zones.</p> <p><bold>Aim</bold>: To evaluate the efficacy of intraoperative computed tomography perfusion navigation (ICTPN) during surgery for high grade gliomas.</p> <p><bold>Materials and methods</bold>: This prospective non-randomized study included 142 patients (76 men and 66 women) with morphologically verified diagnosis of glioblastoma or diffuse astrocytoma grade 4 (World Health Organization 2021 criteria), who had surgery from 2016 to 2022. The ICTPN-based procedures were performed in 94 patients, with 55 with gross total and 39 with subtotal tumor resection. The control group included 48 patients with non-ICTPN-based surgical procedures. All patients were treated with standard adjuvant chemoradiation therapy. The efficacy of surgery was assessed every 3 months. The study endpoint was any tumor progression. The duration of the follow-up was 15 months. Baseline and contrast-enhanced preoperative imaging and postoperative follow-up assessments were performed with a 3T magnetic resonance imaging scanner (General Electric Discovery W750). ICTPN was done with a 32 slice computed tomography scanner (Toshiba Aquilion LB).</p> <p><bold>Results</bold>: In the totally resected ICTPN group, the mean duration of the relapse-free period was 13.05 months; the relapse-free survival at 6 and 12 months was 92 and 55%, respectively (p &lt; 0.001). These results were significantly better than those in the subtotally resected ICTPN patients (8.98 months, 66 and 9%, respectively; log rank test for Kaplan-Meier curves, p &lt; 0.001) and in non-ICTPN patients (5.81 months, 23 and 0%, respectively, log rank test, p &lt; 0.001).</p> <p><bold>Conclusion</bold>: ICTPN enables a more objective assessment of the tumor borders and the extent of its resection, as well as relapse-free survival benefits for the patients.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование</bold>. Главная задача хирургического лечения глиобластом – обеспечение максимально возможной циторедукции. Перфузионная компьютерная томография обладает неинвазивными инструментами для оценки опухолевого кровотока, позволяет отображать границы опухоли и наиболее злокачественные ее участки.</p> <p><bold>Цель</bold> – оценить эффективность применения методики интраоперационной компьютерной томографической навигации с перфузионным исследованием (иКТсПИ) в хирургии высокозлокачественных глиом.</p> <p><bold>Материал и методы</bold>. В проспективное нерандомизированное исследование включены 142 пациента (76 мужчин и 66 женщин) с морфологически верифицированным диагнозом глиобластомы или диффузной астроцитомой grade 4 (критерии Всемирной организации здравоохранения, 2021), перенесшие хирургическое лечение в период с 2016 по 2022 г. Операционное лечение с применением методики иКТсПИ выполнено 94 пациентам, из них 55 проведена тотальная резекция опухоли, а 39 – субтотальная. Контрольную группу составили 48 пациентов, которым было проведено хирургическое лечение без применения методики иКТсПИ. Все пациенты получали стандартную адъювантную химиолучевую терапию. Оценка эффективности хирургического лечения осуществлялась каждые 3 месяца. Конечной точкой исследования было выявление продолженного роста опухоли. Глубина катамнеза составила 15 месяцев. Предоперационные и контрольные послеоперационные исследования выполняли на магнитно-резонансном томографе General Electric Discovery W750 3Т до и после контрастного усиления. иКТсПИ проводили при помощи 32-срезового компьютерного томографа модели Toshiba Aquilion LB.</p> <p><bold>Результаты</bold>. В группе с иКТ (тотальная резекция) средняя продолжительность безрецидивного периода составила 13,05 месяца. Безрецидивная выживаемость через 6 месяцев была 92% и через 12 месяцев – 55%, что значительно превысило аналогичные показатели в группе с иКТ (субтотальная резекция)– 8,98 месяца, 66 и 9% соответственно (лог-ранк тест кривых выживаемости групп 1 и 2, p &lt; 0,001) и группе без иКТ – 5,81 месяца, 23 и 0% (лог-ранк тест кривых выживаемости групп 1 и контрольной, p &lt; 0,001).</p> <p><bold>Заключение</bold>. Использование методики иКТсПИ способствует более объективной оценке границ опухоли и степени ее резекции, а также увеличению продолжительности жизни пациентов без рецидива.</p></trans-abstract><kwd-group xml:lang="en"><kwd>glioblastoma</kwd><kwd>navigation</kwd><kwd>intraoperative computed tomography</kwd><kwd>perfusion</kwd><kwd>tumor boundaries</kwd><kwd>extent of resection</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>глиобластома</kwd><kwd>навигация</kwd><kwd>интраоперационная компьютерная томография</kwd><kwd>перфузия</kwd><kwd>границы опухоли</kwd><kwd>степень резекции опухоли</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Dixon L, Lim A, Grech-Sollars M, Nandi D, Camp S. Intraoperative ultrasound in brain tumor surgery: A review and implementation guide. Neurosurg Rev. 2022;45(4):2503–2515. doi: 10.1007/s10143-022-01778-4.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):3–8. doi: 10.3171/2011.2.jns10998.</mixed-citation></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Goryaynov SA, Potapov AA, Okhlopkov VA, Batalov AI, Afandiev RO, Belyaev AYu, Aristov AA, Caveleva TA, Zhukov VYu, Loshchenov VB, Gusev DV, Zakharova NE. Metabolic navigation during brain tumor surgery: analysis of a series of 403 patients. Russian Journal of Neurosurgery. 2022;24(4):46–58. doi: 10.17650/1683-3295-2022-24-4-46-58.</mixed-citation><mixed-citation xml:lang="ru">Горяйнов СА, Потапов АА, Охлопков ВА, Баталов АИ, Афандиев РО, Беляев АЮ, Аристов АА, Cавельева ТА, Жуков ВЮ, Лощенов ВБ, Гусев ДВ, Захарова НЕ. Метаболическая навигация в хирургии опухолей головного мозга: анализ серии 403 пациентов. Нейрохирургия. 2022;24(4):46–58. doi: 10.17650/1683-3295-2022-24-4-46-58.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><mixed-citation>Pope WB, Brandal G. Conventional and advanced magnetic resonance imaging in patients with high-grade glioma. Q J Nucl Med Mol Imaging. 2018;62(3):239–253. doi: 10.23736/S1824-4785.18.03086-8.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Levenson CW, Morgan TJ, Twigg PD Jr, Logan TM, Schepkin VD. Use of MRI, metabolomic, and genomic biomarkers to identify mechanisms of chemoresistance in glioma. Cancer Drug Resist. 2019;2(3):862–876. doi: 10.20517/cdr.2019.18.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Talybov R, Beylerli O, Mochalov V, Prokopenko A, Ilyasova T, Trofimova T, Sufianov A, Guang Y. Multiparametric MR Imaging Features of Primary CNS Lymphomas. Front Surg. 2022;9:887249. doi: 10.3389/fsurg.2022.887249.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Onishi S, Kajiwara Y, Takayasu T, Kolakshyapati M, Ishifuro M, Amatya VJ, Takeshima Y, Sugiyama K, Kurisu K, Yamasaki F. Perfusion Computed Tomography Parameters Are Useful for Differentiating Glioblastoma, Lymphoma, and Metastasis. World Neurosurg. 2018;119:e890–e897. doi: 10.1016/j.wneu.2018.07.291.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Wang K, Li Y, Cheng H, Li S, Xiang W, Ming Y, Chen L, Zhou J. Perfusion CT detects alterations in local cerebral flow of glioma related to IDH, MGMT and TERT status. BMC Neurol. 2021;21(1):460. doi: 10.1186/s12883-021-02490-4.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Jia ZZ, Shi W, Shi JL, Shen DD, Gu HM, Zhou XJ. Comparison between perfusion computed tomography and dynamic contrast-enhanced magnetic resonance imaging in assessing glioblastoma microvasculature. Eur J Radiol. 2017;87:120–124. doi: 10.1016/j.ejrad.2016.12.016.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Maarouf R, Sakr H. A potential role of CT perfusion parameters in grading of brain gliomas. Egypt J Radiol Nucl Med. 2015;46(4):1119–1128. doi: 10.1016/j.ejrnm.2015.07.002.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Maral H, Ertekin E, Tunçyürek Ö, Özsunar Y. Effects of Susceptibility Artifacts on Perfusion MRI in Patients with Primary Brain Tumor: A Comparison of Arterial Spin-Labeling versus DSC. AJNR Am J Neuroradiol. 2020;41(2):255–261. doi: 10.3174/ajnr.A6384.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Wu J, Al-Zahrani A, Beylerli O, Sufianov R, Talybov R, Meshcheryakova S, Sufianova G, Gareev I, Sufianov A. Circulating miRNAs as Diagnostic and Prognostic Biomarkers in High-Grade Gliomas. Front Oncol. 2022;12:898537. doi: 10.3389/fonc.2022.898537.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507. doi: 10.1056/NEJMra0708126.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Grochans S, Cybulska AM, Simińska D, Korbecki J, Kojder K, Chlubek D, Baranowska-Bosiacka I. Epidemiology of Glioblastoma Multiforme-Literature Review. Cancers (Basel). 2022;14(10):2412. doi: 10.3390/cancers14102412.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014;15(9):e395–e403. doi: 10.1016/S1470-2045(14)70011-7.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Aydin S, Fatihoğlu E., Koşar PN, Ergün E. Perfusion and permeability MRI in glioma grading. Egypt J Radiol Nucl Med. 2020;51(2). doi: 10.1186/s43055-019-0127-3.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Ishikawa E, Sugii N, Matsuda M, Kohzuki H, Tsurubuchi T, Akutsu H, Takano S, Mizumoto M, Sakurai H, Matsumura A. Maximum resection and immunotherapy improve glioblastoma patient survival: a retrospective single-institution prognostic analysis. BMC Neurol. 2021;21(1):282. doi: 10.1186/s12883-021-02318-1.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Haddad AF, Young JS, Morshed RA, Berger MS. FLAIRectomy: Resecting beyond the Contrast Margin for Glioblastoma. Brain Sci. 2022;12(5):544. doi: 10.3390/brainsci12050544.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Broen MPG, Smits M, Wijnenga MMJ, Dubbink HJ, Anten MHME, Schijns OEMG, Beckervordersandforth J, Postma AA, van den Bent MJ. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro Oncol. 2018;20(10):1393–1399. doi: 10.1093/neuonc/noy048.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>van Dijken BRJ, van Laar PJ, Smits M, Dankbaar JW, Enting RH, van der Hoorn A. Perfusion MRI in treatment evaluation of glioblastomas: Clinical relevance of current and future techniques. J Magn Reson Imaging. 2019;49(1):11–22. doi: 10.1002/jmri.26306.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Li C, Yan JL, Torheim T, McLean MA, Boonzaier NR, Zou J, Huang Y, Yuan J, van Dijken BRJ, Matys T, Markowetz F, Price SJ. Low perfusion compartments in glioblastoma quantified by advanced magnetic resonance imaging and correlated with patient survival. Radiother Oncol. 2019;134:17–24. doi: 10.1016/j.radonc.2019.01.008.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Delgado-López PD, Corrales-García EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. 2016;18(11):1062–1071. doi: 10.1007/s12094-016-1497-x.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Hopyan JJ, Gladstone DJ, Mallia G, Schiff J, Fox AJ, Symons SP, Buck BH, Black SE, Aviv RI. Renal safety of CT angiography and perfusion imaging in the emergency evaluation of acute stroke. AJNR Am J Neuroradiol. 2008;29(10):1826–1830. doi: 10.3174/ajnr.A1257.</mixed-citation></ref></ref-list></back></article>
